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Background: For melanoma patients with a positive axillary SLN, the extent of ALND remains controversial, with debate over whether a
level III dissection is needed.
Methods: We queried our IRB approved prospective database for patients with a positive axillary SLN who had a level I/II dissection only,
and compared recurrence and complication rates to the existing literature.
Results: Between 1998 and 2008, 270 patients had 285 level I/II ALNDs for a positive SLN. Median number of SLN removed was 2, while
the median number of involved SLN was 1 (range 1–4). An average of 18.7 nodes/ALND were removed, with 13% having positive non-SLN.
Post-operative complications occurred in 31 patients (11%), primarily cellulitis (8%). After a mean follow-up of 44 months, 14 patients had a
regional recurrence in the axillary basin (5%).
Conclusions: The complication rate and regional recurrence rate for patients undergoing a level I/II ALND for a positive SLN are either
lower than or on par with reported series of ALND for level I, II, and III dissections, suggesting that in this setting, the level III dissection
may be of minimal beneﬁt.
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INTRODUCTION
Sentinel lymph node (SLN) biopsy has proven to be safe, accu-
rate, and highly prognostic for recurrence and survival in the setting
of melanoma without clinical evidence of regional metastasis [1].
Patients who do not have evidence of metastasis in the SLN are
spared a completion lymph node dissection (CLND) and the associ-
ated increased risk of complications, however for patients harboring
disease in the SLN, a timely CLND of the draining lymph node
basin is the standard recommendation.
For the axillary lymph nodes, which drain upper extremity and
most upper trunk melanomas, the extent of that subsequent dissec-
tion is in debate. The guidelines established by the German Cancer
Society recommend dissection of levels I–III for axillary CLND [2].
The group from John Wayne Cancer Institute also recommends dis-
section of all three levels in axillary CLND due to the variability of
drainage patterns in second echelon nodes as well as the potential
increased risk of recurrence with a lesser dissection [3]. Furthermore,
the National Comprehensive Cancer Network guidelines state that
for all positive SLN, an anatomically complete dissection of involved
nodal basins is required [4]. However, there is still debate over
whether a level III axillary dissection is necessary in these patients
[5–7]. At our institution, we have been performing level I and II
axillary CLND for most patients with positive SLN. We postulate
that not only does this spare patients the morbidity associated with a
level I–III dissection which can involve transection of the pectoralis
minor at its insertion on the coracoid process and may be associated
with an additional risk of lymphedema [8–12], but it may also
achieve recurrence and survival rates on par with level I–III CLND
reported in the literature.
METHODS
Utilizing our University of Michigan Institutional Review Board
approved comprehensive, prospective melanoma database to identify
a consecutive series of melanoma patients with positive axillary sen-
tinel lymph nodes who underwent a subsequent complete dissection.
We excluded patients under the age of 18 and patients who under-
went ALND for clinically involved disease. Between January 1998
and December 2008, we identiﬁed 294 patients who underwent com-
pletion ALND for a positive SLN. Of these, 24 had levels 1–3 dis-
sected while 270 underwent level 1 and 2 dissections. This latter
group constitutes our ﬁnal sample size for this study. Distant disease
free survival time was determined as the time from wide local exci-
sion and SLN biopsy to the patient’s last visit with no evidence of
metastatic disease. Overall survival time was determined using a
combination of hospital records and the Social Security Death Index
(SSDI) and deﬁned as the time from initial pathologic diagnosis to
death or last visit.
Our SLN technique has been previously published [13]. Patients
undergo same-day preoperative lymphoscinitigraphy in which
99mTc sulfur colloid (CIS-US, Inc., Bedford, MA) is injected intra-
dermally around the primary lesion or biopsy site 2–4 hr prior to
surgery to identify lymphatic basins and in-transit nodes at risk. Af-
ter induction of anesthesia, either isosulfan blue dye or diluted meth-
ylene blue dye is injected intradermally around the primary lesion or
biopsy site and the area is massaged to promote lymphatic ﬂow. Af-
ter approximately 5–10 min, a handheld gamma probe (Navigator
GPS; US Surgical, Cincinnati, OH) is used to identify the area of
maximal counts over the lymphatic basins identiﬁed by preoperative
lymphoscintigraphy. A small incision is made directly overlying the
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hot spot and carried through the subcutaneous tissue in to the node-
bearing fat. Any blue, hot (deﬁned as the hottest node and any other
nodes greater than 10% of the counts per minute of the hottest node)
or palpably suspicious lymph nodes are considered SLNs. SLN
specimens were ﬁxed in 10% neutral-buffered formalin, serially sec-
tioned longitudinally at 2–3 mm intervals, and entirely embedded in
parafﬁn. Hematoxylin and eosin (H&E) staining was performed on
two 5-mm-thick sections from each tissue block. In addition, four
unstained serial sections were prepared for possible future immuno-
histochemical analysis. If SLN(s) were negative by routine light mi-
croscopy, immunohistochemical staining was routinedly performed
using antibodies to the melanoma markers Melan-A (1:12.5 dilution;
DAKO Corporation, Carpinteria, CA) and S-100 protein (1:500 dilu-
tion; DAKO Corporation). Tumor burden of the positive SLNs (i.e.,
percentage of surface area involved) was measured using our previ-
ously described technique [14]. Nonsentinel nodes in the axillary
lymph node dissection (ALND) specimen were evaluated by routine
bivalving and H&E staining.
Level I and II axillary lymph node dissections were deﬁned as
mobilization and retraction of the pectoralis major (to include the
interpectoral nodes) and pectoralis minor to include the level II
lymph nodes. As previously stated, patients who underwent division
of the pectoralis minor muscle to gain access to the level III nodes,
or excision of the level III nodes under the pectoralis major but me-
dial to the pectoralis minor, were excluded from review.
RESULTS
Over a 10-year period from 1998 to 2008, 270 patients with mela-
noma metastatic to an axillary sentinel lymph node underwent a sub-
sequent level I and II axillary dissection. This patient population
consisted of 110 women (41%) and 160 men (59%). The median age
was 50, with a range from 19 to 93 years. Only two patients (1%)
had primary melanomas on the head and neck, while 201 (74%) had
trunk melanomas and 67 (25%) had melanomas of the upper extrem-
ity. Patient and tumor characteristics of the cohort are shown in
Table I.
Of the 270 patients, 51 patients (19%) had drainage to more than
one basin, with 38 patients mapping to bilateral axillae, 7 patients
mapping to both the axilla and groin, 4 mapping to the axilla and
neck and 2 patients mapping to epitrochlear nodes in addition to
axillary nodes. Fifteen of the patients underwent bilateral ALND (for
a total of 285 ALND’s in 270 patients). The median number of SLN
removed was 2 (average 2.8) with a range of 1–20. The median
number of involved SLN was 1 (average 1.8) with a range of 1–4.
Extranodal extension was identiﬁed in 21 (8%), absent in 244 (90%),
and unknown for 5 cases (2%). On the subsequent node dissection,
there was an average of 18.7 nodes in the specimen, ranging from 2
to 50. Of the 285 ALNDs performed, positive non-sentinel lymph
nodes were found in 37 (13%). The mean number of positive
nodes in the ALND specimen was 0.42, ranging from 0 to 38. Post-
operative complications occurred in 31 patients (11%). Infectious
complications, primarily cellulitis requiring antibiotics, occurred in
22 patients (8%). Seroma after drain removal occurred in 6 patients
(2%) and 2 patients (1%) developed an axillary hematoma. One pa-
tient had a temporary winged scapula which resolved with physical
therapy.
The median follow-up for this group was 44 months. There were
six patients for whom no signiﬁcant follow-up after surgery was
available. Among the remaining 264 patients, 6 patients (2%) suf-
fered a local recurrence at the site of the primary melanoma and
19 patients (7%) developed in-transit disease. There were 57 patients
(22%) who ultimately developed distant disease. Our primary
endpoint however, was regional recurrence, and this was seen in
14 patients (5%). Of these 14 patients, 10 (71%) also had distant
recurrences, 60% of which were synchronous to discovery of the
regional recurrence. The remaining four patients developed distant
disease more than 6 months after their regional recurrence was
detected. Four patients have not yet recurred after resection of the
regional recurrence. Four of the 14 axillary recurrences were nodules
in the skin near the ALND incision, while only one was clearly
documented as a level III recurrence. Among the patients who did
have an axillary recurrence, only 2 of 14 (14%) had positive non-
sentinel nodes, compared with 12% of patients who did not recur. At
the point of last follow-up, 191 (71%) were alive, 180 (67%) without
disease, 9 (3%) with disease and 2 (1%) with an unknown disease
status. Seventy-nine patients (29%) had died, 52 (19%) of metastatic
melanoma, 19 (7%) without melanoma, and 8 died of unknown
reasons.
DISCUSSION
The purpose of this retrospective study was to review our institu-
tional experience with level I/II ALND for patients with microscopic
regional disease detected on SLN biopsy, with particular regards to
regional control. We sought to compare our morbidity and recurrence
data to published data for ALND since the advent of SLN for mela-
noma. Unfortunately this objective is limited by a paucity of contem-
porary data speciﬁcally looking at ALND following a positive SLN.
The lion’s share of the literature focuses on either ALND for clini-
cally evident disease, or regional recurrence for nodal dissections
overall, grouping together neck, axillary and inguinal dissections. In
addition, many studies do not speciﬁcally document the extent of the
axillary dissection.
In our series, postoperative complications occurred in 11% of
patients, with infectious complications in 8%. Wrightson et al. [15]
reporting for the Sunbelt Melanoma Group, described a 19.9% com-
plication rate among 262 patients undergoing ALND for a positive
SLN. Although they did not speciﬁcally describe the extent of the
TABLE I. Patient and Tumor Characteristics of the Study Cohort
Average age (range) 50 (19–93)
Gender (male/female) 160 (59%)/110 (41%)
Site
H&N 2 (1%)
Trunk 201 (74%)
Upper extremity 67 (25%)
Histologic subtype
Superficial spreading 132 (49%)
Nodular 75 (28%)
Other/unclassified 62 (23%)
Breslow thickness, median (range) 2.2 mm (0.8–18)
Ulceration
Yes 96 (36%)
No 165 (61%)
Unknown 9 (3%)
Mitotic rate, mean (range) 5.25 (0–38)
Satellitosis
Yes 14 (5%)
No 237 (88%)
Unknown 19 (7%)
Angiolymphatic invasion
Yes 38 (14%)
No 213 (79%)
Unknown 19 (7%)
# SLN removed, mean (range) 2.8 (1–20)
# Pos SLN, mean (range) 1.28 (1–4)
# nodes in ALND, mean (range) 18.68 (4–50)
% with positive NSLN 37 (13%)
SLN, sentinel lymph node; ALND, axillary lymph node dissection.
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ALND, most cases are thought to be level I–III dissections.
Kretschmer et al. [16] reported a 35% short-term complication rate
(20.7% wound infection and 18.9% seroma) in a series of 70 level I–
III dissections. de Vries et al. [17] reported similar results after level
I–III CLND with a 14% wound infection rate and a 36% seroma
rate.
Our primary endpoint of interest was the regional recurrence rate.
With a median follow-up of 44 months, we report a regional recur-
rence rate of 5%. This is very similar to a smaller series (48 patients)
by Guggenheim et al. [18] examining level I and II dissections, in-
cluding level III only when there were clinically suspicious nodes.
With a median follow-up of 38.8 months, they reported a regional
recurrence rate of 4.3%. As a level III dissection was only performed
in one patient, the authors concluded that level III dissections are not
necessary for regional control.
We sought to compare these results to series where level III dis-
sections were routinely performed, but there is a paucity of published
data to compare with. Most studies reporting regional recurrence af-
ter CLND for a positive SLN grouped together all dissected basins.
Gershenwald et al. [19] reported a series of 101 patients who under-
went CLND with a 30-month median follow-up, ﬁnding a 10%
regional recurrence rate. Clary et al. [20] reported a regional recur-
rence rate of 14% among 56 patients undergoing CLND for a posi-
tive SLN, with a median follow-up of 27 months. Leiter et al. [21]
reported a 19.1% regional recurrence rate after CLND. In all three of
these studies, it is not speciﬁed how many patients had axillary
recurrences after ALND, nor the extent of the ALND performed.
Veenstra et al. [22] report a 4% regional recurrence rate overall, and
did specify that when an ALND was performed, levels I–III were
included, however they did not tease out the axillary recurrence rate
speciﬁcally.
Despite multiple references in the literature to the ‘‘controversy’’
of whether a level III dissection is necessary, there are very few
published papers addressing this particular issue. In our series of
level I and II only ALND’s for a positive SLN, our regional recur-
rence rate is lower than, or on par with, comparable series. This
suggests minimal beneﬁt to the routine inclusion of level III nodes in
this situation. However, it is difﬁcult to deﬁne the adequacy of the
ALND based on anatomic landmarks. In many prospective trials, the
number of nodes within the axillary specimen is the benchmark of a
successful dissection. Balch et al. [23] suggested that 10 or more
nodes need to be retrieved in an adequate ALND. Morton et al. [24]
in the MSLT-I trial recommended 15 or more nodes for an ALND
(30 for a neck dissection and 8 for an ILND), and subsequently
reported a 4.2% regional recurrence rate (again, not specifying axil-
lary recurrence rates).
Spillane et al. [25] examined 863 ALND’s performed by Sydney
Melanoma Unit surgeons, who routinely perform level I–III dissec-
tions, and found that the mean number of nodes in the specimen was
21.9, with at least 10 or more nodes in 90% of cases. This included
both ALND’s for a positive SLN and clinically evident axillary
disease. In our series of patients with a positive SLN, where level III
was not speciﬁcally addressed, our mean number of nodes was 18.7.
Less than 10 nodes were retrieved in 28 cases, for a similar 90%
rate of ALND’s with 10 or more nodes. Likewise, the series by
Guggenheim et al. [18] had a median of 18 nodes per level I and II
dissection. These numbers surpass the median number of nodes
found in some studies of level I–III ALND. Therefore an adequate
ALND for a positive SLN may not necessarily have to incorporate
the nodes medial to the pectoralis minor muscle, but should include
meticulous clearance of nodes by landmarks for levels I and II.
A limitation to this study is the retrospective nature of this review.
As this review incorporates the cases of six different surgeons, vari-
ability in technique cannot be accounted for. Complete or partial
level III dissection can be accomplished in some cases without
division of the pectoralis minor muscle, so that what one surgeon
calls a level I and II dissection, another surgeon might consider a
partial level III dissection. However, it must be emphasized that
complete level II dissections were performed, which mandates ample
mobilization of the pectoralis minor muscle. We ﬁnd that the use of
the Thompson axillary retractor helps considerably with this compo-
nent. Careful examination of the specimen and identiﬁcation of pal-
pable or suspicious nodes (macroscopic disease) should also be
employed so that more extensive dissection can be performed selec-
tively. However, many patients have enlarged nodes after a prior
SLN biopsy that are reactive and not malignant, therefore it may be
reasonable to consider frozen section analysis prior to dividing the
pectoralis minor if dissection of level III is being considered.
Other technical points bear mentioning as well, as there are some
aspects to the ALND performed for melanoma that may not be
addressed as strictly by surgeons used to performing an ALND for
breast cancer. The melanoma surgeon must pay particular attention
to the tissue lateral to the thoracodorsal bundle, where the lateral
(axillary) group of nodes is located. These nodes receive most of the
lymph draining from the upper extremity, so they rarely contain
breast cancer metastases but are commonly the ﬁrst group of nodes
draining melanomas on the upper extremity. The thoracodorsal bun-
dle should not be considered the lateral margin. Clearing the lym-
phatic tissue superior to the axillary vein is also important in
preventing recurrence, particularly for melanomas located on the
shoulder or lateral back. The posterior (subscapular) node group con-
sists of 6 or 7 nodes that lie along the posterior wall of the axilla at
the lateral border of the scapula, and receive drainage primarily from
the posterior neck and trunk. Therefore the dissection must extend
sufﬁciently inferior to clear the lowermost reaches of the axilla, and
the nodal tissue must be cleared down to the level of the subscapula-
ris muscle.
In conclusion, our large, single-institution, retrospective series
of level I and II ALND performed for positive SLN among
melanoma patients demonstrate a complication rate of 11% and a
regional recurrence rate of 5%. These results are either lower than or
on par with reported series of ALND for level I, II and III dissec-
tions, suggesting that when ALND is performed for a positive SLN,
the level III dissection may be of minimal beneﬁt with added
morbidity.
REFERENCES
1. Morton DL, Thompson JF, Cochran AJ, et al.: Sentinel-node
biopsy or nodal observation in melanoma. N Engl J Med 2006;
355:1307–1317.
2. Garbe C, Hauschild A, Volkenandt M, et al.: Evidence-based
and interdisciplinary consensus-based German guidelines: Sys-
temic medical treatment of melanoma in the adjuvant and palli-
ative setting. Melanoma Res 2008;18:152–160.
3. Essner R: Surgical treatment of malignant melanoma. Surg Clin
N Am 2003;83:109–156.
4. NCCN: Clinical Practical Guidelines in Oncology- Melanoma.
2011. (Accessed 12/21, 2010, at http://www.nccn.org/profesion-
als/physician_gls/PDF/melanoma.pdf.).
5. Karakousis CP: Therapeutic node dissections in malignant mel-
anoma. Ann Surg Oncol 1998;5:473–482.
6. Meyer T, Merkel S, Gohl J, et al.: Lymph node dissection for
clinically evident lymph node metastases of malignant melano-
ma. Eur J Surg Oncol 2002;28:424–430.
7. Serpell JW, Carne PW, Bailey M: Radical lymph node dissec-
tion for melanoma. ANZ J Surg 2003;73:294–299.
8. Sakorafas GH, Peros G, Cataliotti L, et al.: Lymphedema
following axillary lymph node dissection for breast cancer. Surg
Oncol 2006;15:153–165.
9. Larson D, Weinstein M, Goldberg I, et al.: Edema of the arm as
a function of the extent of axillary surgery in patients with stage
ALND for Melanoma SLN 227
Journal of Surgical Oncology
I–II carcinoma of the breast treated with primary radiotherapy.
Int J Radiat Oncol Biol Phys 1986;12:1575–1582.
10. Silberman H: Axillary lymphadenectomy for breast cancer:
Impact on survival. In: Silberman H, Silberman A, editors.
Surgical oncology: Multidisciplinary approach to difﬁcult prob-
lems. London: Arnold; 2002. pp. 369–385.
11. Kiel K, Rademaker AW: Early-stage breast cancer: Arm edema
after wide excision and breast irradiation. Radiology 1996;1998:
279–283.
12. Suneson BL: Clinical incidence of lymphedema in breast cancer
patients in Jonkoping County, Sweden. Eur J Cancer Care 1996;
5:1–12.
13. Sondak VK, Taylor JM, Sabel MS, et al.: Mitotic rate and youn-
ger age are predictors of sentinel lymph node positivity: Lessons
learned from the generation of a probabilistic model. Ann Surg
Oncol 2004;11:247–258.
14. Frankel TL, Grifﬁth KA, Lowe L, et al.: Do micromorphometric
features of metastatic deposits within sentinel nodes predict
nonsentinel lymph node involvement in melanoma? Ann Surg
Oncol 2008;15:2403–2411.
15. Wrightson WR, Wong SL, Edwards MJ, et al.: Complications
associated with sentinel lymph node biopsy for melanoma. Ann
Surg Onc 2003;10:676–780.
16. Kretschmer L, Thoms KM, Peeters S, et al.: Postoperative mor-
bidity of lymph node excision for cutaneous melanoma-sentinel
lymphonodectomy versus complete regional lymph node dissec-
tion. Melanoma Res 2008;18:16–21.
17. de Vries M, Vonkeman WG, van Ginkel RJ, et al.: Morbidity
after axillary sentinel lymph node biopsy in patients with cuta-
neous melanoma. Eur J Surg Oncol 2005;31:778–783.
18. Guggenheim MM, Hug U, Jung FJ, et al.: Morbidity and recur-
rence after completion lymph node dissection following sentinel
lymph node biopsy in cutaneous malignant melanoma. Ann
Surg 2008;247:687–693.
19. Gershenwald JE, Berman RS, Porter G, et al.: Regional nodal
basin control is not compromised by previous sentinel lymph
node biopsy in patients with melanoma. Ann Surg Oncol 2000;
7:226–231.
20. Clary BM, Brady MS, Lewis JJ, et al.: Sentinel lymph node
biopsy in the management of patients with primary cutaneous
melanoma: Review of a large single-institution experience with
an emphasis on recurrence. Ann Surg 2001;233:250–258.
21. Leiter U, Buettner PG, Bohnenberger K, et al.: Sentinel lymph
node dissection in primary melanoma reduces subsequent re-
gional lymph node metastasis as well as distant metastasis after
nodal involvement. Ann Surg Oncol 17:129–137.
22. Veenstra HJ, van der Ploeg IM, Wouters MW, et al.: Reevalua-
tion of the locoregional recurrence rate in melanoma patients
with a positive sentinel node compared to patients with palpable
nodal involvement. Ann Surg Oncol 17:521–526.
23. Balch CM, Durant JR, Bartolucci AA: The impact of surgical
quality control in multi-institutional group trials involving adju-
vant cancer treatments. Ann Surg 1983;198:164–167.
24. Morton DL, Cochran AJ, Thompson JF, et al.: Sentinel node
biopsy for early-stage melanoma: Accuracy and morbidity in
MSLT-I, an international multicenter trial. Ann Surg 2005;242:
302–313.
25. Spillane AJ, Cheung BL, Stretch JR, et al.: Proposed quality
standards for regional lymph node dissections in patients with
melanoma. Ann Surg 2009;249:473–480.
228 Namm et al.
Journal of Surgical Oncology
